Manganese Composition for ERMCS-Linked mtDNA Replication Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and neurodegenerative disorders associated with aberrant Endoplasmic Reticulum and Mitochondria Contact Sites (ERMCS) are inadequate, and there is a lack of understanding about how these sites regulate mitochondrial DNA replication and maintenance, leading to unaddressed disease progression.
Innovation Solution
A composition comprising manganese (Mn2+) or its pharmaceutically acceptable salts is used to treat diseases with aberrant ERMCS, as it enhances mitochondrial DNA synthesis in cells with impaired ERMCS, supplemented by a diagnostic assay to identify suitable candidates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative disorders, then symptom relief and pain management are achieved, but the underlying disease progression remains unaddressed and no remission occurs
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism of ERMCS dysfunction and mtDNA replication defects as the root cause of neurodegenerative diseases, separating this from the symptomatic treatments currently used. By identifying and addressing the underlying molecular pathology rather than just symptoms, the treatment achieves disease modification rather than temporary symptom relief.
Solution Approach 2:
The patent changes the therapeutic parameter from symptomatic management to restoring specific molecular functions - specifically enhancing mtDNA replication and ERMCS functionality through manganese supplementation. This parameter change shifts the treatment goal from temporary symptom alleviation to restoring fundamental cellular processes, thereby addressing disease progression.
2Ease of manufacture
If there is a lack of understanding about ERMCS regulation of mtDNA replication, then treatment development is hindered, but providing new treatments requires fundamental knowledge of these mechanisms
Solution Approach 1:
The patent performs preliminary research and identification of the ERMCS-mtDNA replication connection before developing the treatment. By first establishing the mechanistic understanding through scientific investigation (identifying ERLIN2, RTN4, GRP75 as key proteins and manganese as the regulating ion), the treatment development is enabled. This preliminary action converts the knowledge gap into actionable therapeutic targets.
Solution Approach 2:
The patent introduces manganese as an intermediary substance that mediates between the ERMCS proteins and mtDNA replication. Manganese serves as the missing link that connects the structural components (ERLIN2, RTN4, GRP75) to the functional outcome (mtDNA synthesis), providing the mechanistic bridge needed for treatment development.
3Productivity
If manganese supplementation is used to enhance mtDNA synthesis, then mitochondrial DNA replication is restored in cells with impaired ERMCS, but the mechanism requires specific cellular conditions to be effective
Solution Approach 1:
The patent applies local quality by targeting manganese supplementation specifically to cells with impaired ERMCS rather than using a universal treatment. The treatment is adapted to the specific cellular condition (dysfunctional ERMCS) and restores mtDNA synthesis locally in affected mitochondria, rather than attempting a blanket approach that would not work in all cellular contexts.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Manganese supplementation increases mitochondrial DNA synthesis in cells with dysfunctional ERMCS, offering a targeted therapeutic approach for neurodegenerative diseases by restoring mtDNA replication.
Implementation Method 1
A composition comprising manganese (Mn2+) or its pharmaceutically acceptable salts is used to treat diseases with aberrant ERMCS, as it enhances mitochondrial DNA synthesis in cells with impaired ERMCS
Data Source
Figure 1A~2C
Figure 3~4B
Figure 5A~6B
AI summary
The invention relates to composition comprising manganese, a solvate or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease in a subject, wherein the subject's cells have fewer than half the number of functional endoplasmic reticulum and mitochondria contact sites than the cells from a subject not suffering from the disease, and to an in vitro method for designing a personalised therapy to a subject suffering from a disease, comprising determining the mtDNA synthesis rate in a biological sample isolate from the subject in the presence and absence of Mn.